Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study.

Item

http://www.wikidata.org/entity/Q38412511

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Low-dose SoluMatrix diclofenac ...... label, Phase III safety study.

@en

type

Item

label

Low-dose SoluMatrix diclofenac ...... label, Phase III safety study.

@en

prefLabel

Low-dose SoluMatrix diclofenac ...... label, Phase III safety study.

@en

P1476

Low-dose SoluMatrix diclofenac ...... label, Phase III safety study.

@en

P2093

Alan Kivitz

http://www.w3.org/2001/XMLSchema#string

Allan Gibofsky

http://www.w3.org/2001/XMLSchema#string

Byron Cryer

http://www.w3.org/2001/XMLSchema#string

Clarence L Young

http://www.w3.org/2001/XMLSchema#string

Jennifer Nezzer

http://www.w3.org/2001/XMLSchema#string

Joseph A Markenson

http://www.w3.org/2001/XMLSchema#string

Marc C Hochberg

http://www.w3.org/2001/XMLSchema#string

Olaolu Imasogie

http://www.w3.org/2001/XMLSchema#string

Roy D Altman

http://www.w3.org/2001/XMLSchema#string

Vibeke Strand

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available).

Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available.

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.

P304

517-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2015.1040716

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25913498

http://www.w3.org/2001/XMLSchema#string

P921

diclofenac

osteoarthritis